Literature DB >> 815437

The defect in mu heavy chain disease protein GLI.

E C Franklin, B Frangione, F Prelli.   

Abstract

Amino acid sequence studies of muHCD protein GLI reveal the absence of the amino terminal 130 residues. The molecule starts at Ala 131 and contains Cys 140, normally involved in the H-L disulfide bridges. Except for the deletion and presumably an extra H-H disulfide bridge involving Cys 140, the remainder of the mu-chain appears normal.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 815437

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  6 in total

1.  A DNA insertion/deletion necessitates an aberrant RNA splice accounting for a mu heavy chain disease protein.

Authors:  A Bakhshi; P Guglielmi; U Siebenlist; J V Ravetch; J P Jensen; S J Korsmeyer
Journal:  Proc Natl Acad Sci U S A       Date:  1986-04       Impact factor: 11.205

Review 2.  Malignant lymphomas--a conceptual understanding of morphologic diversity. A review.

Authors:  R B Mann; E S Jaffe; C W Berard
Journal:  Am J Pathol       Date:  1979-01       Impact factor: 4.307

Review 3.  Genetic determination of antibody specificity. Gene translocation and fusion, the molecular basis for the differentiation of the antibody-producing cell.

Authors:  N Hilschmann; H U Barnikol; H Kratzin; P Altevogt; M Engelhard; S Barnikol-Watanabe
Journal:  Naturwissenschaften       Date:  1978-12

4.  Immunodiagnosis of alpha chain disease.

Authors:  W F Doe; F Danon; M Seligmann
Journal:  Clin Exp Immunol       Date:  1979-05       Impact factor: 4.330

5.  Mouse model for abortive rabies infection of the central nervous system.

Authors:  J S Smith
Journal:  Infect Immun       Date:  1981-01       Impact factor: 3.441

6.  Production of Autoreactive Heavy Chain-Only Antibodies in Systemic Lupus Erythematosus.

Authors:  Shu Xu; Hong Yang; Yue Zhuo; Yangsheng Yu; Hongyan Liao; Song Li; Yinshi Yue; Kaihong Su; Zhixin Zhang
Journal:  Front Immunol       Date:  2020-05-05       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.